Physician profile
John M Mccarty
NPI 1073603627
$97,345.26
in general payments reported to CMS, 2019-2025
13 companies · $25K in 2025
The $25K reported for 2025 was more than what 90% of Medical Oncology providers received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $14K · 2020: $6,750 · 2021: $2,480 · 2022: $25K · 2023: $11K · 2024: $13K · 2025: $25K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $31K · Consulting Fee: $14K · Food and Beverage: $2,957 · Travel and Lodging: $936 · Education: $43.25.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $31,080.00 |
| Consulting Fee | $13,730.00 |
| Food and Beverage | $2,956.53 |
| Travel and Lodging | $936.24 |
| Education | $43.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kite Pharma, INC. | $75,650.35 | 2019-2025 | Yescarta |
| Celgene Corporation | $14,926.92 | 2019-2021 | |
| Legend Biotech USA INC. | $2,805.00 | 2022 | |
| National Marrow Donor Program | $2,109.49 | 2022-2025 | |
| Jazz Pharmaceuticals INC. | $1,100.00 | 2019 | |
| Incyte Corporation | $245.75 | 2024-2025 | Niktimvo, Jakafi |
| Novartis Pharmaceuticals Corporation | $150.76 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $127.51 | 2022-2024 | Abecma |
| Seagen INC. | $80.04 | 2021 | |
| Iovance Biotherapeutics, INC. | $64.55 | 2024 | Amtagvi |
| Astrazeneca Pharmaceuticals LP | $43.25 | 2025 | Enhertu |
| Genetix Biotherapeutics INC | $41.64 | 2025 | Lyfgenia |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Mccarty listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.